Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
Pituitary. 2010 Sep;13(3):266-86. doi: 10.1007/s11102-009-0210-2.
The Endocrine Tumor Summit convened in December 2008 to address 6 statements prepared by panel members that reflect important questions in the treatment of acromegaly and carcinoid syndrome. Data pertinent to each of the statements were identified through review of pertinent literature by one of the 9-member panel, enabling a critical evaluation of the statements and the evidence supporting or refuting them. Three statements addressed the validity of serum growth hormone (GH) and insulin-like growth factor-I (IGF-I) concentrations as indicators or predictors of disease in acromegaly. Statements regarding the effects of preoperative somatostatin analog use on pituitary surgical outcomes, their effects on hormone and symptom control in carcinoid syndrome, and the efficacy of extended dosing intervals were reviewed. Panel opinions, based on the level of available scientific evidence, were polled. Finally, their views were compared with those of surveyed community-based endocrinologists and neurosurgeons.
内分泌肿瘤峰会于 2008 年 12 月召开，旨在解决由专家组准备的 6 项声明，这些声明反映了肢端肥大症和类癌综合征治疗中的重要问题。通过专家组的 9 名成员之一对相关文献的审查，确定了与每个声明相关的数据，从而对声明及其支持或反驳的证据进行了批判性评估。有 3 项声明涉及血清生长激素 (GH) 和胰岛素样生长因子-I (IGF-I) 浓度作为肢端肥大症疾病的指标或预测因子的有效性。对术前生长抑素类似物使用对垂体手术结果的影响、对类癌综合征中激素和症状控制的影响以及延长给药间隔的疗效进行了审查。根据现有科学证据的水平，征求了专家组的意见。最后，将他们的观点与调查的社区内分泌学家和神经外科医生的观点进行了比较。
